Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on the real-world data from Spain and Italy, which demonstrated meaningful objective response rates.</li></ul>

Redeye comments on the real-world data from Spain and Italy, which demonstrated meaningful objective response rates.

Oncopeptides: Real World Data from Spain and Italy

<ul><li>Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian markets.</li><li>Although still early in its rollout, there are now signs that Pepaxti may become a commercial success in Europe.</li><li>The rights issue of SEK150m announced at the same time should cover operations through 2026 and until there is a positive cash flow.</li></ul>

Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian markets.Although still early in its rollout, there are now signs that Pepaxti may become a commercial success in Europe.The rights issue of SEK150m announced at the same time should cover operations through 2026 and until there is a positive cash flow.

Oncopeptides Q2 2025: Funded Until Profitability

<ul><li>Redeye provides its first take on Oncopeptides' Q2 report.</li><li>The sales number for Q2 had already been communicated and was slightly above our forecast.</li><li>Expenses were in line with our forecast.</li></ul>

Redeye provides its first take on Oncopeptides' Q2 report.The sales number for Q2 had already been communicated and was slightly above our forecast.Expenses were in line with our forecast.

Oncopeptides Q2 2025: Another Strong Q/Q Growth and Rights Issue

Sweden

Oncopeptides AB is a biotech company that engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company's lead product is Pepaxti (melflufen), a peptide-drug conjugate for the treatment of relapsed or refractory multiple myeloma. Oncopeptides' proprietary Peptide Drug Conjugate (PDC) platform is designed to rapidly and selectively deliver cytotoxic agents into cancer cells.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oncopeptides (ONCO SS)

Oncopeptides: Real World Data from Spain and Italy

Redeye comments on the real-world data from Spain and Italy, which demonstrated meaningful objective response rates.

Redeye

Oncopeptides Q2 2025: Funded Until Profitability

Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian...

Redeye

Oncopeptides Q2 2025: Another Strong Q/Q Growth and Rights Issue

Redeye provides its first take on Oncopeptides' Q2 report. The sales number for Q2 had already been communicated and was slightly above our...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)